Trial Profile
Non Interventional Study Dealing With the Use of Bevacizumab (Avastin) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms ENCOURAGE
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 16 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 27 Apr 2013 New trial record